While Sandoz has emerged as the front-runner to get a generic version of GlaxoSmithKline’s respiratory blockbuster Advair to the US market, rival Hikma has not given up despite a major setback.

UK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for approval of its generic of GlaxoSmithKline’s blockbuster respiratory drug Advair. Hikma has been ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

Hikma recently received the Food and Drug Administration’s permission for a new generic, and the company also launched two new generic products. The FDA approved Hikma's first generic ...

For example, the Hikma Pharmaceuticals PLC (LON:HIK) share price is up 23% in the last 5 years, clearly besting the market return of around 3.1% (ignoring dividends). However, more recent returns ...